Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €112.11 EUR
Change Today -1.46 / -1.28%
Volume 34.0
VX1 On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
As of 1:58 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

vertex pharmaceuticals inc (VX1) Snapshot

Open
€112.42
Previous Close
€113.57
Day High
€114.58
Day Low
€111.49
52 Week High
08/10/15 - €130.50
52 Week Low
09/4/14 - €70.45
Market Cap
27.4B
Average Volume 10 Days
657.1
EPS TTM
--
Shares Outstanding
244.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERTEX PHARMACEUTICALS INC (VX1)

vertex pharmaceuticals inc (VX1) Related Businessweek News

View More BusinessWeek News

vertex pharmaceuticals inc (VX1) Details

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing its research and early-stage development programs. It markets KALYDECO (ivacaftor) to treat patients of six years of age and older with CF who have the mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene in the United States, Australia, Canada, and the European Union. The company also provides INCIVEK for the treatment of adults with genotype 1 hepatitis C virus infection. In addition, it is developing CFTR correctors, including lumacaftor in combination with ivacaftor, which has completed Phase III development program; and VX-661 in combination with ivacaftor, which is in Phase III development program. Further, it identifies and develops next-generation CFTR corrector compounds; and is involved in the research and early-stage development programs, including programs in the areas of oncology and neurology. Vertex Pharmaceuticals Incorporated sells its products principally to specialty pharmacy providers and wholesalers in North America, as well as government-owned and supported customers in international markets. The company has collaboration agreements with Cystic Fibrosis Foundation Therapeutics Incorporated; BioAxone Biosciences, Inc.; and Janssen Pharmaceuticals, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

1,830 Employees
Last Reported Date: 02/13/15
Founded in 1989

vertex pharmaceuticals inc (VX1) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.1M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $650.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $789.1K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $600.0K
Special Counsel to the Chief Executive Office...
Total Annual Compensation: $465.0K
Compensation as of Fiscal Year 2014.

vertex pharmaceuticals inc (VX1) Key Developments

Vertex Pharmaceuticals Incorporated Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Revenue Guidance for the Full Year of 2015

Vertex Pharmaceuticals Incorporated announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $166,076,000 against $138,421,000 a year ago. Loss from operations was $171,164,000 against $180,542,000 a year ago. Loss from continuing operations before provision for income taxes was $190,861,000 against $158,396,000 a year ago. Net loss attributable to Vertex was $188,848,000 or $0.78 per basic and diluted share against $159,382,000 or $0.68 per basic and diluted share a year ago. Loss from continuing operations attributable to Vertex was $188,848,000 or $0.78 per basic and diluted share against $159,089,000 or $0.68 per basic and diluted share a year ago. Non-GAAP net loss attributable to Vertex was $130,683,000 or $0.54 per basic and diluted share against $141,718,000 or $0.61 per basic and diluted share a year ago. Non-GAAP total revenues were $159,908,000 against $121,976,000 a year ago. Loss from continuing operations was $220,992,000 against $159,089,000 a year ago. For the six months, the company reported total revenues of $304,585,000 against $256,872,000 a year ago. Loss from operations was $343,149,000 against $396,584,000 a year ago. Loss from continuing operations before provision for income taxes was $389,266,000 against $389,704,000 a year ago. Net loss attributable to Vertex was $387,454,000 or $1.61 per basic and diluted share against $391,839,000 or $1.68 per basic and diluted share a year ago. Loss from continuing operations attributable to Vertex was $387,454,000 or $1.61 per basic and diluted share against $391,200,000 or $1.68 per basic and diluted share a year ago. Loss from continuing operations was $419,696,000 against $391,200,000 a year ago. Non-GAAP net loss attributable to Vertex was $279,059,000 or $1.16 per basic and diluted share against $293,008,000 or $1.26 per basic and diluted share a year ago. Non-GAAP total revenues were $295,348,000 against $230,157,000 a year ago. The company revised revenue guidance for the full year of 2015. The company now expects KALYDECO net revenues of $575 to $590 million for 2015. The prior range, first provided on January 28, 2015, was for KALYDECO net revenues of $560 to $580 million for 2015. The company is growing their revenues, and they expect to show additional growth from ORKAMBI. They will continue to invest to create even more medicines and support access to those medicines already approved.

Vertex Pharmaceuticals Incorporated to Report Q2, 2015 Results on Jul 29, 2015

Vertex Pharmaceuticals Incorporated announced that they will report Q2, 2015 results at 5:00 PM, US Eastern Standard Time on Jul 29, 2015

Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015

Vertex Pharmaceuticals Incorporated, Q2 2015 Earnings Call, Jul 29, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VX1:GR €112.11 EUR -1.46

VX1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $64.58 USD +1.67
BioMarin Pharmaceutical Inc $126.51 USD +0.06
Incyte Corp $115.88 USD -0.19
Jazz Pharmaceuticals PLC $162.18 USD -2.07
Sigma-Aldrich Corp $139.46 USD -0.10
View Industry Companies
 

Industry Analysis

VX1

Industry Average

Valuation VX1 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 48.5x
Price/Book 34.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 46.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERTEX PHARMACEUTICALS INC, please visit www.vrtx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.